報價延遲最少15分鐘:2026/06/02 01:15 EDT
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
0.9803 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-1.46/-0.94
|
|
企業價值
53.20M
|
| 資產負債 |
|
每股賬面淨值
0.08
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
22.00K
|
|
每股收益
0.10
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| Senti Biosciences Holdings Inc, formerly known as Senti Biosciences Inc, is a clinical-stage biotechnology company developing cell and gene therapies using its gene circuit platform for patients with incurable diseases. Its gene circuits, created from proprietary DNA sequences, are designed to reprogram cells to sense, compute, and respond to cellular environments. Its product candidates are to kill cancer cells, spare healthy cells, increase specificity, and control drug expression. Its candidate, SENTI-202, is a logic-gated off-the-shelf CAR-NK cell therapy for blood cancers, currently in a Phase 1 clinical trial in the United States and Australia for relapsed or refractory hematological malignancies, including Acute Myeloid Leukemia (AML). |
